What does it take to develop improved seasonal influenza vaccines or the elusive universal vaccines? It requires thinking outside the box, learning from the literature, asking the smart questions, collaborating across disciplines, and of course, doing science with the utmost integrity.
At CIVR-HRP, collaboration is a cornerstone of our success. Improving influenza vaccines demands that we look beyond our own labs to speed advances. Especially when developing more durable, broadly protective, and longer-lasting influenza vaccines that will be effective in even our most vulnerable populations.
The third CIVR-HRP meeting will feature talks by leading experts in the field and the trainees that are doing the science, panel discussions, and opportunities to network. We hope that sharing the achievements of the teams will showcase the power of collaboration and help stimulate innovative new strategies to transform the development of improved vaccines.
The meeting is free to all registered participants. The hotel for the event is The Peabody Hotel in downtown Memphis.
The deadline to submit abstracts is April 1, 2024
For more information, please contact civrhrp@stjude.org
Agenda
-
Sunday, April 21, 2024 6:00-9:00 pm Welcome Dinner and Reception
The Pocket (Tailor's Union)
115 Union Ave., Memphis -
Monday, April 22, 2024 7:15 am Transportation to St Jude Children’s Research Hospital 7:30 am Registration desk open
Continental breakfastOpening Session: Stacey Schultz-Cherry, convener 8:30-8:40 am Welcome and Objectives of the Meeting
Stacey Schultz-Cherry, St. Jude Children’s Research Hospital
Ted Ross, Cleveland Clinic8:40-8:45 am Welcome from NIAID
Kentner Singleton, DAIT NIAID
8:45 – 8:55 am Welcome from the Department of Host-Microbe Interactions
Victor Torres, Member and Chair Dept of Host-Microbe Interactions, St. Jude Children’s Research Hospital
8:55 – 9:10 am Welcome to St Jude Children’s Research Hospital
J. Paul Taylor, Executive Vice President/Scientific Director, Member and Chair Dept of Cell & Molecular Biology, St. Jude Children’s Research Hospital
Vaccine Design: Nada Abbadi, convener 9:15 – 9:35 am Developing Next-Generation Influenza Vaccines
Ted Ross, Cleveland Clinic, Florida
9:40 – 9:55 am Live-attenuated COBRA influenza vaccines provoke a broad immune response, reduce influenza disease severity, and impair viral transmission in a ferret model
Victoria Meliopoulos, St. Jude Children’s Research Hospital
10:00 – 10:15 am COBRA mRNA vaccines elicit protective antibodies against antigenically drifted H1N1 and H3N2 influenza viruses
James Allen, Cleveland Clinic
10:20 – 10:40 am Refreshment break 10:40 – 10:55 am Computationally optimized neuraminidase vaccines closely resemble wild-type NA proteins and elicit broadly reactive and protective monoclonal antibodies
Nada Abbadi, University of Georgia
11:00 – 11:15 am AAV expressing a COBRA-designed influenza hemagglutinin generates a protective adaptive immune response with a single dose
Kristin Wiggins, St Jude Children’s Research Hospital
Structure: John Dzimianski, convener 11:20 – 11:40 am Immunogenicity of the Foldon trimerization domain and efforts to shield it
Rebecca DuBois, University of California Santa Cruz
11:45 – 1:00 pm Lunch (8th floor, i4ARC) 1:00 – 1:45 pm KEYNOTE
Development of a recombinant influenza vaccine – Flublok. Implications for a universal influenza vaccine
Manon Cox, President and CEO, NextWaveBio
1:50 – 2:10 pm HA stalk stability and its effect on vaccine immunogenicity and broadly neutralizing antibodies
Charles Russell, St Jude Children’s Research Hospital
2:15 – 2:30 pm Assessing the structural boundaries of broadly reactive antibody interactions with diverse H3 influenza hemagglutinin proteins
John Dzimianski, University of California Santa Cruz
Adjuvants and stability: Luis Ontiveros, convener 2:35 – 2:55 pm A thermostable COBRA subunit vaccine without carrier mediated responses: zinc-carnosine coordination polymer
Kristy Ainslie, University of North Carolina Chapel Hill
3:00 – 3:20 pm Refreshment break 3:20 – 3:40 pm Use of the slow-delivery platform, VacSIM, shapes the host immune response to increase protection against influenza infection
Jarrod Mousa, Florida State University
3:45 – 4:00 pm COBRA intranasal vaccine adjuvanted with nanoparticulate mast cell agonist MP12W and CpG
Luis Ontiveros, University of North Carolina Chapel Hill
4:05 – 4:20 pm TRAC-478 EM: Development and Manufacturing of Novel Adjuvant Systems of the Future
Eric Ward, Inimmune Corp
Vulnerable populations: Ericka Roubidoux, convener 4:25 – 4:45 pm Weight loss does not improve vaccine efficacy in mice
Stacey Schultz-Cherry, St Jude Children’s Research Hospital
4:50 – 5:05 pm Influenza vaccine delivery platforms induce distinct antibody profiles during pregnancy that impact protection of offspring
Ericka Roubidoux, St Jude Children’s Research Hospital
5:10 – 5:25 pm Understanding the impact of gestational SARS-CoV-2 infections on maternal and infant clinical outcomes (ARTMIS Study)
Juan Arias, St Jude Children’s Research Hospital
5:30 – 5:50 pm Mammary gland and breast milk immunity to influenza viruses
Stephanie Langel, Case Western Reserve University
6:00 – 8:00 pm Conference dinner (8th floor, i4ARC) Shuttles available at 8:00 pm -
Tuesday, April 23, 2024 7:15 am Transportation to St Jude Children’s Research Hospital 7:30 am Registration desk open
Continental breakfastT-Cells: Chantelle White, convener 8:30-8:50 am Tracking vaccine responses using the TCR repertoire
Paul Thomas, St Jude Children’s Research Hospital
8:55-9:15 am The impact of host infection history on influenza vaccine responses
Andrea Sant, University of Rochester
9:20-9:35 am Investigating the impact of the novel adjuvant R-DOTAP on the establishment of influenza vaccine-induced cellular immunity
Chantelle White, University of Rochester
B Cells and Serology, Lauren Immink, convener 9:40-10:00 am Identification of Rare Human Memory B cells targeting a Pandemic-Threat H5N1 Virus
Jenna Guthmiller, University of Colorado School of Medicine
10:05-10:20 am Refreshment break 10:20-10:35 am Defining the impacts of obesity on influenza vaccine-elicited memory B cells
Lauren Immink, University of Colorado School of Medicine
10:40-10:55 am Identifying mechanistic drivers of poor B cell responses to influenza vaccine in individuals with obesity
Tyler Ripperger, St Jude Children’s Research Hospital
11:00-11:20 am Stimulation of functional antibody responses through concurrent influenza and COVID-19 vaccinations
Ryan McNamara, Ragon Institute of Mass General, MIT, and Harvard
11:25-11:40 am Longitudinal profiling and dissection of the antibody response following influenza vaccination
Giuseppe A. Sautto, Cleveland Clinic Florida Research & Innovation Center
Modeling: Savannah Hammerton, convener 11:45 am-12:05 pm Antibody ceiling effects following influenza vaccination
Andreas Handel, University of Georgia
12:10-12:25 pm Using a defined titer-protection model to estimate vaccine efficacy and difference in vaccine efficacy in age- and dose-based groups
Savannah Hammerton, University of Georgia
12:30-12:55 pm Panel Discussion: Ways forward for CIVR-HRP 12:55-1:00 pm Closing 1:00 pm Boxed lunches available 1:30 pm Campus and/or GMP tours
